

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/613,633	07/03/2003	Eric M. Weaver	P03592US03	4613
22885	5 7590 05/02/2005		EXAMINER	
•	OORHEES & SEASE	KIM, YUNSOO		
801 GRAND AVENUE SUITE 3200 DES MOINES, IA 50309-2721			ART UNIT	PAPER NUMBER
			1644	

DATE MAILED: 05/02/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		I A Planette No.					
Office Action Summany		Application No.	Applicant(s)				
		10/613,633	WEAVER ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Yunsoo Kim	1644				
Period fo	The MAILING DATE of this communicator Reply	tion appears on the cover sh	eet with the correspondence ad	dress -			
THE - Exte after - If the - If NC - Failt Any	MAILING DATE OF THIS COMMUNICA MAILING DATE OF THIS COMMUNICA COMMUNICA COMMUNICA COMMUNICA COMMUNICA COMMUNICA COMMUNICA COMMUNICA COMMUNICAC	TION. 7 CFR 1.136(a). In no event, however, ation. 1ys, a reply within the statutory minimury period will apply and will expire SIX by statute, cause the application to be	may a reply be timely filed m of thirty (30) days will be considered timely (6) MONTHS from the mailing date of this come ABANDONED (35 U.S.C. § 133).	y. ommunication.			
Status							
1) 又	Responsive to communication(s) filed o	n 14 March 2005.					
		☐ This action is non-final.					
·	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims						
5)□ 6)⊠ 7)□	Claim(s) 9-21 is/are pending in the apple 4a) Of the above claim(s) is/are version claim(s) is/are allowed. Claim(s) 9-21 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction	vithdrawn from consideratio					
Applicat	ion Papers						
9)	The specification is objected to by the E	xaminer.	•				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)	Replacement drawing sheet(s) including the The oath or declaration is objected to by	•	• • •	• •			
Priority (under 35 U.S.C. § 119						
12) <u>□</u> a)	Acknowledgment is made of a claim for All b) Some * c) None of: 1. Certified copies of the priority doc 2. Certified copies of the priority doc 3. Copies of the certified copies of the application from the International See the attached detailed Office action for	cuments have been receive cuments have been receive he priority documents have Bureau (PCT Rule 17.2(a)	ed. ed in Application No been received in this National).	Stage			
Attachmen	it(s)						
1) Notice 2) Notice 3) Inform	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO- mation Disclosure Statement(s) (PTO-1449 or PTO- er No(s)/Mail Date 7/3/03.	948) Pap D/SB/08) 5) 🔲 Not	erview Summary (PTO-413) per No(s)/Mail Date tice of Informal Patent Application (PTC per:	O-152)			

Application/Control Number: 10/613,633 Page 2

Art Unit: 1644

DETAILED ACTION

1. Claims 9-21 are pending.

2. Applicants' election without traverse of Group II drawn to claims 9-21 in the reply filed on 3/14/05 is acknowledged.

Therefore, claims 9-21 drawn to a method of improving weight gain by administering a supplement are currently being examined.

- 3. Applicants' IDS filed on 7/3/03 has been acknowledged. However, foreign patents and non-patent literature have not been considered as Applicants failed to provide the copies of the references.
- 4. Claims 10-21 are objected to because of the following informalities: claims 10-21 fail to use a proper article "the" and "administered" in claim 20.
- 5. Claim 15 is objected to under 37 CFR. 1.75(d)1 as failing to provide proper antecedent basis for the claimed subject matter. Claim 15 recites "about". The specification discloses "approximately" in p.16, line 9. The metes and bounds of the terms "about" and "approximately" are different. Applicants are invited to use the language of the specification in the claim.
- The following is a quotation of the second paragraph of 35 U.S.C. 112:
 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 7. Claims 9-21 are indefinite being dependent on a non-elected claim and should be written as independent claims.
- 8. Claims 14 and 15 are rejected under 35 U.S.C. 112, second paragraph, as being improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. "0.1% by weight" in claim 15 broadens the scope of claim 14.

Application/Control Number: 10/613,633 Page 3

Art Unit: 1644

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 10. Claims 9-21 are rejected under 35 U.S.C. 102(b) as being anticipated by Newson et al. (U.S. Pat. No. 4,096,244).

Newson et al. teach a use of blood-derived immunoglobulin in a supplement for a piglet (col. 3-4, Example 1). Newson et al. further teach the serum is pooled from swine or cattle (col. 3, lines 1-3), decreasing mortality (col. 6, table 1, % survival increased), at least 15% of immunoglobulin by weight and water stable (col. 3, lines 54-55, in aqueous mixture, col. 4, lines 16-42), additives (i.e. vitamin or mineral, col. 4, lines 15-36, col. 5, lines 38-44), in aqueous mixture (col. 4, lines, 16-42), 0.5g immunoglobulin/hd/day or more (1g to 3g, col. lines 39-43) and young piglets (from day one to 21st day, col. 5-6 under example 1).

The claimed functional limitation (improving weight gain) would be inherent property of the referenced formulation. The reference composition is applied to the identical population as in claimed invention.

As on p. 10, 1st paragraph of the specification of the instant application, post weaning piglets have been considered as underweight, claim 13 has been included.

Thus, prior art teachings anticipate the instant claimed invention.

No claims are allowable.

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yunsoo Kim whose telephone number is 571-272-3176. The examiner can normally be reached on Monday thru Friday 8:30 - 5:00PM.

Application/Control Number: 10/613,633 Page 4

Art Unit: 1644

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Yunsoo Kim
Patent Examiner
Technology Center 1600

April 18, 2005

Patrick J. Nolan, Ph.D.

Primary Examiner

Technology Center 1600

April 18, 2005